pre randomisation tumour specimen (Foundation Medicine Inc)
Structured Review
Pre Randomisation Tumour Specimen, supplied by Foundation Medicine Inc, used in various techniques. Bioz Stars score: 99/100, based on 2432 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisation+system/FoundationOne+CDx/pm41422862-70-13-20
Average 99 stars, based on 2432 article reviews
Images
Related Articles
Next-Generation Sequencing:Article Title: Precision medicine in patients with advanced biliary tract cancer. Article Snippet: .. Internal/academic (e.g., MOSCATO 01/02 [22,23], MATCH-R [24,25], SHIVA [26] , BOB [NCT03767075]) or commercial Analysis:Article Title: Multicenter Evaluation of Decentralized Homologous Recombination Deficiency Testing for Enhanced Molecular Diagnosis of Ovarian Cancer † Article Snippet: .. Tempus xT CDx (Tempus AI, Inc., USA), the most recently approved test for tumor-only indication [ ], and Profiling:Article Title: Optimal Genetic Profiling in Sarcoma Requires Quality Control and Comparative Studies Article Snippet: G enomic profiling in sarcomas is a relatively new technology that has important implications for the treatment of this heterogeneous group of tumors 1 .. It has led to the possibility of not only further classifying or diagnosing sarcoma subtypes but also identifying targetable alterations 2 .. This has led to a shift in management such that multiple sarcomas now have a viable medical treatment option where none was previously available. |
